Intech Investment Management LLC Has $2.18 Million Holdings in Krystal Biotech, Inc. $KRYS

Intech Investment Management LLC increased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 11.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,078 shares of the company’s stock after buying an additional 1,239 shares during the quarter. Intech Investment Management LLC’s holdings in Krystal Biotech were worth $2,178,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Brooklyn Investment Group boosted its holdings in shares of Krystal Biotech by 291.7% in the 1st quarter. Brooklyn Investment Group now owns 141 shares of the company’s stock valued at $25,000 after buying an additional 105 shares during the last quarter. Twin Tree Management LP acquired a new stake in shares of Krystal Biotech in the 1st quarter valued at approximately $29,000. Fifth Third Bancorp boosted its holdings in shares of Krystal Biotech by 159.1% in the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company’s stock valued at $31,000 after buying an additional 105 shares during the last quarter. Smartleaf Asset Management LLC lifted its holdings in Krystal Biotech by 128.3% during the 1st quarter. Smartleaf Asset Management LLC now owns 315 shares of the company’s stock valued at $58,000 after purchasing an additional 177 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Krystal Biotech during the 1st quarter valued at $74,000. Institutional investors and hedge funds own 86.29% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on KRYS shares. Citigroup reaffirmed a “neutral” rating and set a $166.00 price target (down previously from $176.00) on shares of Krystal Biotech in a report on Tuesday, August 5th. Chardan Capital cut their price target on Krystal Biotech from $219.00 to $216.00 and set a “buy” rating for the company in a report on Friday, August 22nd. HC Wainwright reaffirmed a “buy” rating and set a $240.00 price target on shares of Krystal Biotech in a report on Monday. Finally, Bank of America cut their price target on Krystal Biotech from $193.00 to $192.00 and set a “buy” rating for the company in a report on Tuesday, July 22nd. Six research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $209.00.

Krystal Biotech Stock Up 8.4%

Krystal Biotech stock opened at $155.71 on Tuesday. Krystal Biotech, Inc. has a 12-month low of $122.80 and a 12-month high of $207.84. The business’s 50-day moving average price is $147.13 and its two-hundred day moving average price is $152.27. The stock has a market cap of $4.51 billion, a PE ratio of 31.65 and a beta of 0.66.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, August 4th. The company reported $1.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.08 by $0.21. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%.The firm had revenue of $96.04 million for the quarter, compared to analysts’ expectations of $95.42 million. As a group, analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 13,435 shares of the business’s stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $150.30, for a total transaction of $2,019,280.50. Following the sale, the insider directly owned 1,443,276 shares in the company, valued at approximately $216,924,382.80. The trade was a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold a total of 49,800 shares of company stock valued at $7,487,943 in the last quarter. Insiders own 13.70% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).